29.05.2016 07:15:21
|
Biotech Stocks Facing FDA Decision In June
(RTTNews) - The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts.
The new molecular entity to get the FDA's blessing is Roche's Tecentriq, a PD-L1 inhibitor, to treat the most common type of bladder cancer, called urothelial carcinoma. Tecentriq was approved on May 18, 2016, four months ahead of the decision date.
The FDA decision that came as a shocker was that on AstraZeneca's hyperkalemia drug ZS-9. The company was handed down a Complete Response Letter for ZS-9 on May 27, 2016, referring to observations arising from a pre-approval manufacturing inspection. However, no new clinical data was sought by the regulatory agency.
With June just around the corner, it's time to take a look at the upcoming FDA decisions of the month.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
31.12.24 |
Minuszeichen in New York: Dow Jones zum Handelsende leichter (finanzen.at) | |
31.12.24 |
Handel in New York: Dow Jones legt am Nachmittag den Rückwärtsgang ein (finanzen.at) | |
31.12.24 |
Dow Jones-Handel aktuell: Dow Jones zeigt sich schwächer (finanzen.at) | |
31.12.24 |
Dow Jones 30 Industrial-Titel Merck-Aktie: So viel hätten Anleger mit einem Investment in Merck von vor 3 Jahren verdient (finanzen.at) | |
31.12.24 |
Dow Jones-Handel aktuell: Dow Jones zum Start des Dienstagshandels mit Zuschlägen (finanzen.at) | |
30.12.24 |
Montagshandel in New York: Dow Jones verbucht zum Ende des Montagshandels Verluste (finanzen.at) | |
27.12.24 |
Zurückhaltung in New York: Dow Jones notiert zum Handelsende im Minus (finanzen.at) | |
27.12.24 |
Börse New York in Rot: Dow Jones verliert zum Start (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Gilead Sciences Inc. | 88,81 | -0,89% | |
Merck Co. | 96,00 | -0,41% | |
Pfizer Inc. | 25,84 | -0,39% | |
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 20,40 | -5,56% |